Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Return to homepage

Lexaria Bioscience Corp. (C:LXX)

Business Focus: N/A

Get the company report for the most recent outlook updated daily
Sep 16, 2021 08:30 am ET
Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Hypertension: The Silent Killer Making Loud Noise for Investors.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News...
Sep 15, 2021 08:30 am ET
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Throw Hat into Hypertension Ring with Proprietary Drug-Delivery System
via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and...
Aug 06, 2021 08:30 am ET
Lexaria Bioscience Corp. (NASDAQ: LEXX) on Forefront of Exciting Hypertension Innovation
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, Innovators in the Space.” To hear the AudioPressRelease,...
Aug 04, 2021 08:30 am ET
Lexaria Bioscience Corp. (NASDAQ: LEXX) Leads the Way in Innovating Hypertension Treatment
via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and...
Jul 08, 2021 03:15 pm ET
CSE Bulletin: Delist - Lexaria Bioscience Corp. (LXX)
Toronto, Ontario--(Newsfile Corp. - le 8 juillet/July 2021) At the request of the company the common shares of Lexaria Bioscience Corp. will be delisted at market close on July 8, 2021.
Jul 05, 2021 08:00 am ET
Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
Jul 05, 2021 06:07 am ET
Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets
Kelowna, British Columbia - TheNewswire - July 5, 2021 - Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that on June 30, 2021 it made a request to voluntarily delist its common shares from the Canadian Securities Exchange (the “CSE”). It is expected that the close of business on Wednesday, July 7, 2021 will be the final trading day for Lexaria on the CSE. At the open of the trading day on July 8, 2021, the Company’s shares will only trade on the NASDAQ Capital Markets ("Nasdaq").
Jun 29, 2021 04:05 pm ET
Lexaria Announces 2021 Annual Meeting Results
KELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the 2021 Annual Meeting (the 'Meeting').
Jun 29, 2021 02:06 am ET
Lexaria Announces 2021 Annual Meeting Results
Kelowna, British Columbia – TheNewswire - June 29, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces the results of the 2021 Annual Meeting (the "Meeting").
Jun 15, 2021 07:05 am ET
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs
DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2
Jun 15, 2021 05:06 am ET
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs
DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2
Jun 09, 2021 07:00 am ET
Lexaria Provides Progress Report on Six R&D Programs
KELOWNA, BC / ACCESSWIRE / June 9, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this progress report on several studies within its 2021 applied research and development (R&D) program. Other studies actively underway and planned will be reported on separately.
Jun 09, 2021 05:06 am ET
Lexaria Provides Progress Report on Six R&D Programs
 
Jun 08, 2021 02:06 am ET
Lexaria Announces Issuance of Options
Kelowna, British Columbia – TheNewswire – June 8, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces the issuance of 87,935 stock options.
Jun 07, 2021 07:00 am ET
Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1
KELOWNA, BC / ACCESSWIRE / June 7, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to report that treatment and dosing in its human clinical study (HYPER-H21-1) have been completed ahead of schedule.
Jun 07, 2021 05:06 am ET
Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1
Kelowna, British Columbia – TheNewswire - June 7, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to report that treatment and dosing in its human clinical study (HYPER-H21-1) have been completed ahead of schedule.
Jun 03, 2021 07:00 am ET
Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus
KELOWNA, BC / ACCESSWIRE / June 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that remdesivir and ebastine processed with DehydraTECH were effective at inhibiting the COVID-19 SARS-CoV-2 virus using an in vitro screening assay in infected cells in Lexaria study VIRAL-C21-3.
Jun 03, 2021 05:06 am ET
Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus
Kelowna, British Columbia - TheNewswire - June 3, 2021 - Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that remdesivir and ebastine processed with DehydraTECH were effective at inhibiting the COVID-19 SARS-CoV-2 virus using an in vitro screening assay in infected cells in Lexaria study VIRAL-C21-3.
May 20, 2021 07:05 am ET
Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever
KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce successful test results of two new "DehydraTECH™ 2.0" cannabidiol ("CBD") formulations in its second 2021 applied research and development study program, HYPER-A21-2.
May 20, 2021 05:05 am ET
Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever
Kelowna, British Columbia, May 20, 2021 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce successful test results of two new “DehydraTECH™ 2.0” cannabidiol (“CBD”) formulations in its second 2021 applied research and development study program, HYPER-A21-2.
May 12, 2021 07:05 am ET
Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted
KELOWNA, BC / ACCESSWIRE / May 12, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces further expansion of its intellectual property portfolio with its first-ever patent granted in India.
May 12, 2021 05:05 am ET
Lexaria Strengthens its International Patent Portfolio to 19 Patents Granted
 New patent granted in India bolsters worldwide patent coverage, adding to existing patents in the EU, the U.S., and Australia
May 07, 2021 09:00 am ET
Lexaria to Present at the Benzinga Global Small Cap Conference on May 13, 2021 at 3:50 p.m. ET
Lexaria Recently Announced Favorable Data on Its First Animal Study, As Well as the Commencement of Its First Human Clinical Study, Under Its 2021 Hypertension R&D Program
May 07, 2021 07:05 am ET
Lexaria to Present at the Benzinga Global Small Cap Conference on May 13, 2021 at 3:50 p.m. ET
 
May 07, 2021 02:05 am ET
Lexaria Announces Cancellation of Options
Kelowna, British Columbia – TheNewswire – May 7, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces the cancellation of 87,935 stock options.
May 06, 2021 06:00 am ET
BTV Explores Investment Options in Life Sciences
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2021) - On national TV Sat. May 8 & Sun. May 9, 2021 - BTV-Business Television explores life science investment opportunities including psychedelic-based therapies and home COVID-19 tests.
May 06, 2021 05:05 am ET
Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1
Kelowna, British Columbia – TheNewswire - May 6, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce successful outcomes in its first sets of data from its 2021 applied research and development (R&D) study programs.
Apr 27, 2021 02:28 pm ET
Lexaria Bioscience Corp., Proprietary Drug Delivery Technology, CEO Clip Video
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2021) - Lexaria Bioscience Corp. (CSE: LXX) (NASDAQ: LEXX) - Chris Bunka, CEO and Chairman of Lexaria Bioscience, speaks about the Company's proprietary drug delivery technology, DehydraTECH™.
Apr 26, 2021 02:04 am ET
Lexaria Awards Stock Options
Kelowna, British Columbia – TheNewswire – April 26, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces it has issued stock options to consultants, employees, directors and officers of the Company.
Apr 22, 2021 07:00 am ET
Lexaria Commences Human Clinical Hypertension Study
KELOWNA, BC / ACCESSWIRE / April 22, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that its human clinical hypertension study HYPER-H21-1 is officially underway. Lexaria's patented DehydraTECH CBD formulation will be examined to assess its ability to control blood pressure and assess impact on inflammation.
Apr 22, 2021 05:04 am ET
Lexaria Commences Human Clinical Hypertension Study
Kelowna, British Columbia, April 22, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that its human clinical hypertension study HYPER-H21-1 is officially underway. Lexaria’s patented DehydraTECH CBD formulation will be examined to assess its ability to control blood pressure and assess impact on inflammation.
Apr 15, 2021 04:05 pm ET
Lexaria Appoints New Chief Financial Officer and Issues Consultant Warrants
KELOWNA, BC / ACCESSWIRE / April 15, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the appointment of a new Chief Financial Officer and the issuance of share purchase warrants to third party consultants.
Apr 15, 2021 11:04 am ET
Lexaria Appoints New Chief Financial Officer and Issues Consultant Warrants
Kelowna, British Columbia – TheNewswire - April 15, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces the appointment of a new Chief Financial Officer and the issuance of share purchase warrants to third party consultants.
Apr 14, 2021 07:00 am ET
Lexaria's DehydraTECHTM Technology Utilized in Amari's "Everyday Calm," Named a Top CBD Product Pick by New Hope Network
KELOWNA, BC / ACCESSWIRE / April 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announced that its corporate client Amari Corp.'s "Everyday Calm" CBD product was named a Top CBD Product Pick by New Hope Network, host of the industry-leading Natural Products Expo conference events. Hundreds of CBD products competed to be among "New Hope Network editors' Top Picks
Apr 14, 2021 05:04 am ET
Lexaria's DehydraTECH(TM) Technology Utilized in Amari's "Everyday Calm," Named a Top CBD Product Pick by New Hope Network
Click Image To View Full Size
Apr 06, 2021 07:05 am ET
Lexaria to Evaluate DehydraTECH(TM) in Multiple New Markets
KELOWNA, BC / ACCESSWIRE / April 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, will begin important new applied research and development (R&D) study programs planned in 2021.
Apr 06, 2021 05:04 am ET
Lexaria to Evaluate DehydraTECH(TM) in Multiple New Markets
Mar 24, 2021 07:00 am ET
Lexaria Technology Generates Positive Stability Testing for World-Class Ready-to-Drink CBD Beverages
KELOWNA, BC / ACCESSWIRE / March 24, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announced positive results from its extended stability testing, which has reported unparalleled stability for bottled CBD-containing beverages prepared using its technology.
Mar 24, 2021 05:03 am ET
Lexaria Technology Generates Positive Stability Testing for World-Class Ready to Drink CBD Beverages
Mar 23, 2021 07:00 am ET
Lexaria to Present at the Benzinga Biotech Small Cap Conference on March 24, 2021 at 9:45 AM ET
KELOWNA, BC / ACCESSWIRE / March 23, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that CEO Chris Bunka is presenting at the Benzinga Biotech Small Cap Conference to be held on March 24-25, 2021. Complimentary investor registration can be accessed through the conference link below.
Mar 22, 2021 05:03 am ET
Lexaria to Present at the Benzinga Biotech Small Cap Conference on March 24, 2021 at 9:45 AM ET
 
Mar 16, 2021 07:00 am ET
Lexaria's Antiviral Drug Evaluation Program Progressing
KELOWNA, BC / ACCESSWIRE / March 16, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces extensive progress in two of the four planned antiviral drug studies in its 2021 applied research and development (R&D) program.
Mar 16, 2021 05:03 am ET
Lexaria's Antiviral Drug Evaluation Program Progressing
Mar 15, 2021 07:00 am ET
Rapid Progress in Hypertension Studies by Lexaria
KELOWNA, BC / ACCESSWIRE / March 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces extensive progress in five studies focused on the performance of DehydraTECHTM CBD as a treatment for hypertension. Three human clinical trials and two animal research trials are part of the Company's 2021 applied research and development (R&D) program. The Company has additional studies under design, to be announced when available. Lexaria's DehydraTECH
Mar 15, 2021 05:03 am ET
Rapid Progress in Hypertension Studies by Lexaria
Mar 11, 2021 07:10 am ET
Lexaria to Present and Meet with Investors One-on-One at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021
Lexaria recently expanded its hypertension R&D program evaluating effectiveness of DehydraTECH-processed CBD to three human clinical studies and two animal studies
Mar 11, 2021 05:03 am ET
Lexaria to Present and Meet with Investors One-on-One at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021
 
Feb 16, 2021 02:02 am ET
Lexaria Enters Investor Relations Agreement
Feb 11, 2021 07:15 am ET
Lexaria Expands R&D Program to Address US$28 Billion Hypertension Market with Addition of Two Human Clinical Studies
KELOWNA, BC / ACCESSWIRE / February 11, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces significant progress in its 2021 applied research and development (R&D) program with additional focus on hypertension.
Feb 11, 2021 05:02 am ET
Lexaria Expands R&D Program to Address US$28 Billion Hypertension Market with Addition of Two Human Clinical Studies
 
Feb 01, 2021 06:30 am ET
Lexaria Provides Guidance on Upcoming R&D
KELOWNA, BC / ACCESSWIRE / February 1, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces applied R&D programs to begin immediately.
Feb 01, 2021 04:02 am ET
Lexaria Provides Guidance on Upcoming R&D
Kelowna, British Columbia - TheNewswire - February 1, 2021 – Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces applied R&D programs to begin immediately.
Jan 28, 2021 10:09 am ET
Lexaria Bioscience Corp. Discusses $11 Million Public Offering and 2021 Goals with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - January 28, 2021) - The Stock Day Podcast welcomed Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) ("the Company"), a company with the proprietary drug delivery technology, DehydraTECH™, which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream. CEO of the Company, Chris Bunka, joined Stock Day host Everett Jolly.
Jan 15, 2021 03:35 pm ET
Lexaria Appoints New Board Member
KELOWNA, BC / ACCESSWIRE / January 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors.
Jan 15, 2021 06:30 am ET
Lexaria Bioscience Corp. Announces Closing of $11 Million Public Offering with Full Exercise of Underwriter Option to Purchase Additional Shares and Warrants
KELOWNA, BC / ACCESSWIRE / January 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company") today announced the closing of its previously announced underwritten public offering (the "Offering") of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In c
Jan 15, 2021 04:01 am ET
Lexaria Bioscience Corp. Announces Closing of $11 Million Public Offering with Full Exercise of Underwriter Option to Purchase Additional Shares and Warrants
KELOWNA, British Columbia – TheNewswire - January 15, 2021 – Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connec
Jan 15, 2021 01:01 am ET
Lexaria Appoints New Board Member
Kelowna, British Columbia – TheNewswire - January 15, 2021 – Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors.
Jan 12, 2021 07:00 am ET
Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering
KELOWNA, BC / ACCESSWIRE / January 12, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company") today announced that its common stock and warrants will begin trading on the Nasdaq Capital Market on January 12, 2021, under the symbols "LEXX" and "LEXXW," respectively.
Jan 12, 2021 05:01 am ET
Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering
Kelowna, British Columbia - TheNewswire - January 12, 2021 - Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company”) today announced that its common stock and warrants will begin trading on the Nasdaq Capital Market on January 12, 2021, under the symbols “LEXX” and “LEXXW,” respectively.
Jan 08, 2021 04:45 pm ET
Lexaria Announces Effective Date for Reverse Stock Split
KELOWNA, BC / ACCESSWIRE / January 8, 2021 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it intends to effect a reverse stock split of its common stock effective as of 4:30 pm EST on January 11, 2021 (the "Reverse Split").
Jan 08, 2021 02:01 am ET
Lexaria Announces Effective Date for Reverse Stock Split
Kelowna, British Columbia – TheNewswire - January 8, 2021 – Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it intends to effect a reverse stock split of its common stock effective as of 4:30 pm EST on January 11, 2021 (the “Reverse Split”).
Dec 22, 2020 06:30 am ET
Lexaria Expands COVID-19 Drug Research Program Utilizing Proprietary DehydraTECH
Remdesivir is one of several drugs to be evaluated
Dec 22, 2020 04:12 am ET
Lexaria Expands COVID-19 Drug Research Program Utilizing Proprietary DehydraTECH
Remdesivir is one of several drugs to be evaluated
Dec 10, 2020 06:50 am ET
Lexaria Closes Sale of Non-Pharmaceutical THC-Related Assets
Asset Sale in Preparation for Potential US National Securities Exchange Listing
Dec 10, 2020 04:12 am ET
Lexaria Closes Sale of Non-Pharmaceutical THC-Related Assets
Asset Sale in Preparation for Potential US National Securities Exchange Listing
Dec 08, 2020 09:00 am ET
Lexaria Bioscience Corp. Discusses Demonstration of Improved Oral Delivery for Antiviral Drugs with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - December 8, 2020) - The Stock Day Podcast welcomed Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX), the developer of DehydraTECH™, a proprietary drug delivery technology that improves the way active pharmaceutical ingredients (APIs) enter the bloodstream. CEO of the Company, Chris Bunka, joined Stock Day host Everett Jolly.
Dec 07, 2020 04:12 am ET
Lexaria to Highlight its DehydraTECH(TM) Technology at Four Upcoming Investor Conferences
- Benzinga Global Small Cap Conference on December 8th
Dec 01, 2020 06:30 am ET
Lexaria’s Patented Technology Significantly Enhances Oral Delivery of Antiviral Drugs
Demonstrates Improved Delivery of Two Classes of Drugs in Use Against HIV/AIDS and under investigation Against SARS-CoV-2/COVID-19
Dec 01, 2020 04:12 am ET
Lexaria's Patented Technology Significantly Enhances Oral Delivery of Antiviral Drugs
Demonstrates Improved Delivery of Two Classes of Drugs in Use Against HIV/AIDS and under investigation Against SARS-CoV-2/COVID-19
Nov 19, 2020 06:30 am ET
Lexaria Bioscience Sells Non-Pharmaceutical THC-Related Assets for CDN$3.85M
Asset Sale in Preparation for US National Securities Exchange Listing
Nov 19, 2020 04:11 am ET
Lexaria Bioscience Sells Non-Pharmaceutical THC-Related Assets for CDN$3.85M
Asset Sale in Preparation for US National Securities Exchange Listing
Nov 05, 2020 06:45 am ET
Lexaria Bioscience Advances 2021 Strategic Initiatives
Lexaria Focusing on Four Core Business Segments:
Nov 05, 2020 04:11 am ET
Lexaria Bioscience Advances 2021 Strategic Initiatives
Lexaria Focusing on Four Core Business Segments:
Oct 26, 2020 02:30 pm ET
Lexaria Bioscience Extends Warrant Term
KELOWNA, BC / ACCESSWIRE / October 26, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in oral drug delivery platforms, has determined to extend the term of an aggregate 1,823,745 share purchase warrants (the "Warrants"), which were issued pursuant to a private placement of units.
Oct 26, 2020 12:10 pm ET
Lexaria Bioscience Extends Warrant Term
Kelowna, British Columbia - TheNewswire – October 26, 2020 – Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in oral drug delivery platforms, has determined to extend the term of an aggregate 1,823,745 share purchase warrants (the “Warrants”), which were issued pursuant to a private placement of units.  
Oct 22, 2020 06:15 am ET
Lexaria Proprietary DehydraTECH-Enabled CBD Powders Business Growing Faster than Expected
Growth now expected to exceed 500% from fiscal Q4 2020 to fiscal Q1 2021
Oct 22, 2020 04:10 am ET
Lexaria Proprietary DehydraTECH-Enabled CBD Powders Business Growing Faster than Expected
Growth now expected to exceed 500% from fiscal Q4 2020 to fiscal Q1 2021
Oct 21, 2020 06:15 am ET
Lexaria Bioscience Granted First European Patent for DehydraTECH Technology
New patent includes method of treatment claims for a broad range of disease conditions including use of:
Oct 21, 2020 04:10 am ET
Lexaria Bioscience Granted First European Patent for DehydraTECH(TM) Technology
New patent includes method of treatment claims for a broad range of disease conditions including use of:
Oct 09, 2020 02:10 am ET
Lexaria Provides Update on Ongoing Business Relationship with Altria Ventures
Kelowna, British Columbia – October 9, 2020 – Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms updates the status of the business relationship between Altria Ventures Inc. (“Altria”) and Lexaria Nicotine LLC (“Lexaria Nicotine”).
Sep 29, 2020 06:25 am ET
Lexaria Receives Conditional Ethics Board Approval for Pilot Human Study Using DehydraTECH Technology in Delivering Antiviral Drugs
Company Raises Commitment to Antiviral Research with Launch of Rodent Antiviral Drug Delivery Study with Potential COVID-19 Applications
Sep 29, 2020 04:09 am ET
Lexaria Receives Conditional Ethics Board Approval for Pilot Human Study Using its DehydraTECH technology in Delivering Antiviral Drugs
Company Raises Commitment to Antiviral Research with Launch of Rodent Antiviral Drug Delivery Study with Potential COVID-19 Applications
Sep 23, 2020 06:15 am ET
Lexaria Receives Orders for 4.4 Million Servings of DehydraTECH-Enabled CBD Powders
KELOWNA, BC / ACCESSWIRE / September 23, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CNSX:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that it is in receipt of purchase-order commitments for approximately 4.4 million CBD servings of its patented DehydraTECHTM enabled CBD powders, to be processed during the Company's fiscal Q1 2021 which ends November 30, 2020.
Sep 23, 2020 04:09 am ET
Lexaria Receives Orders for 4.4 Million Servings of DehydraTECH-Enabled CBD Powders
Kelowna, British Columbia – TheNewswire - September 23, 2020 – Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that it is in receipt of purchase-order commitments for approximately 4.4 million CBD servings of its patented DehydraTECHTM enabled CBD powders, to be processed during the Company’s fiscal Q1 2021 which ends November 30, 2020.
Sep 22, 2020 06:15 am ET
Lexaria Bioscience Continues to Grow its Patent Portfolio
KELOWNA, BC / ACCESSWIRE / September 22, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announces that it has received another new granted patent in the USA.
Sep 22, 2020 04:09 am ET
Lexaria Bioscience Continues to Grow its Patent Portfolio
Kelowna, British Columbia – TheNewswire – September 22, 2020 – Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announces that it has received another new granted patent in the USA.
Sep 16, 2020 06:25 am ET
Lexaria Bioscience Supports Corporate Growth Initiatives by its Licensee, Cannadips CBD by the Boldt Runners Corporation
KELOWNA, BC / ACCESSWIRE / September 16, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, proudly supports the corporate growth initiatives underway by its DehydraTECHTM licensee, Boldt Runners Corporation ("Boldt Runners"), owners of the Cannadips CBD brand.
Sep 16, 2020 04:09 am ET
Lexaria Bioscience Supports Corporate Growth Initiatives by its Licensee, Cannadips CBD by the Boldt Runners Corporation
Kelowna, British Columbia – TheNewswire – September 16, 2020 – Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, proudly supports the corporate growth initiatives underway by its DehydraTECHTM licensee, Boldt Runners Corporation (“Boldt Runners”), owners of the Cannadips CBD brand.
Aug 31, 2020 04:49 pm ET
IIROC Trade Resumption - LXX
VANCOUVER, BC, Aug. 31, 2020 /CNW/ - Trading resumes in:
Aug 31, 2020 04:01 pm ET
Lexaria Bioscience Announces R&D Agreement With British American Tobacco
KELOWNA, BC / ACCESSWIRE / August 31, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered a research and development ("R&D") framework agreement with British American Tobacco (Investments) Limited ("BAT") to investigate Lexaria's technology for potential use in nicotine products.
Aug 31, 2020 02:51 pm ET
IIROC Trading Halt - LXX
VANCOUVER, BC, Aug. 31, 2020 /CNW/ - The following issues have been halted by IIROC:
Aug 31, 2020 02:08 am ET
Lexaria Bioscience announces R&D agreement with British American Tobacco
Kelowna, British Columbia – TheNewswire – August 31, 2020 – Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that it has entered a research and development (“R&D”) framework agreement with British American Tobacco (Investments) Limited (“BAT”) to investigate Lexaria’s technology for potential use in nicotine products.
Aug 20, 2020 07:17 am ET
Lexaria Bioscience to Present at the LD 500 Virtual Conference
Company to discuss its Phase I R&D program with Altria Ventures Inc., for oral forms of nicotine delivery utilizing its patented DehydraTECH™ technology
Jul 28, 2020 06:30 am ET
Lexaria BioScience Receives Ethics Board Approval to Conduct Exploratory Clinical Study using Cannabidiol for Blood Pressure Reduction
Complements previously published data that cites Lexaria's TurboCBD to demonstrate a significant 5% reduction in mean arterial blood pressure
Jul 28, 2020 04:07 am ET
Lexaria BioScience Receives Ethics Board Approval to Conduct Exploratory Clinical Study using Cannabidiol for Blood Pressure Reduction
Complements previously published data that cites Lexaria’s TurboCBD to demonstrate a significant 5% reduction in mean arterial blood pressure
Jul 21, 2020 06:15 am ET
Lexaria BioScience Files Application with Senior U.S. Stock Exchange for Uplisting
KELOWNA, BC / ACCESSWIRE / July 21, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has filed an application with a senior stock exchange in the United States to request an uplisting of the Company's common stock.
Jul 21, 2020 04:07 am ET
Lexaria BioScience Files Application with Senior U.S. Stock Exchange for Uplisting
Kelowna, British Columbia – TheNewswire - July 21, 2020 - Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that it has filed an application with a senior stock exchange in the United States to request an uplisting of the Company’s common stock.
Jul 16, 2020 06:15 am ET
Altria and Lexaria Conclude Phase I Research and Development Program
R&D Program Utilized Lexaria's Patented DehydraTECHTM Technology for Oral Nicotine Delivery
Jul 16, 2020 04:07 am ET
Altria and Lexaria Conclude Phase I Research and Development Program
R&D Program Utilized Lexaria’s Patented DehydraTECHTM Technology for Oral Nicotine Delivery
Jun 29, 2020 04:15 pm ET
Lexaria Bioscience Engages Investor Relations and Capital Markets Advisory Firm for its Shareholder Communications Program
KELOWNA, BC / ACCESSWIRE / June 29, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announced it has retained IRTH Communications, LLC ("IRTH") to provide investor relations and communications services to the Company in compliance with regulatory guidelines.
Jun 29, 2020 02:06 am ET
Lexaria Bioscience Engages Investor Relations and Capital Markets Advisory Firm for its Shareholder Communications Program
KELOWNA, BC – TheNewswire - June 29, 2020 - Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announced it has retained IRTH Communications, LLC (“IRTH”) to provide investor relations and communications services to the Company in compliance with regulatory guidelines. 
Jun 24, 2020 06:15 am ET
Lexaria Announces 2020 Annual and Special Meeting Results
KELOWNA, BC / ACCESSWIRE / June 24, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria") announces the results of the 2020 Annual and Special Meeting (the "Meeting").
Jun 24, 2020 04:06 am ET
Lexaria Announces 2020 Annual and Special Meeting Results
Kelowna, British Columbia - TheNewswire – June 24, 2020 – Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”) announces the results of the 2020 Annual and Special Meeting (the “Meeting”).  
Jun 18, 2020 06:30 am ET
Lexaria Bioscience Applies for NIH Grant for COVID-19 Therapy Studies and Receives New Expanded Health Canada License
KELOWNA, BC / ACCESSWIRE / June 18, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has submitted a grant application to the U.S. National Institutes of Health (NIH) entitled "In vitro and in vivo animal exploratory pharmacokinetic and preliminary efficacy modelling of select orally administered antiviral compounds following DehydraTECH formulati
Jun 18, 2020 04:06 am ET
Lexaria Bioscience Applies for NIH Grant for COVID-19 Therapy Studies and Receives New Expanded Health Canada License
KELOWNA, BC - TheNewswire - June 18, 2020 - Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has submitted a grant application  to the U.S. National Institutes of Health (NIH) entitled "In vitro and in vivo animal exploratory pharmacokinetic and preliminary efficacy modelling of select orally administered antiviral compounds following DehydraTECH formulation enhancement." pursuant to their National Institute of Allergy and Infectious Diseases (NIAID) Funding Opportunity Announcement (FOA) RFA-
Jun 04, 2020 11:06 am ET
Early Warning News Release
KELOWNA, BC – TheNewswire - June 4, 2020 – Christopher Bunka, Chief Executive Officer and director of Lexaria Bioscience Corp. (the “Company”), (CNSX:LXX.CN) of 100 – 740 McCurdy Road, Kelowna, BC  V1X 2P7, announces his intention to file an early warning report (the “EWR”) in accordance with National Instrument 62-104 – Take-Over Bids and Issuer Bids (“NI 62-104”) and National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues (“NI 62-103”) as promulgated by the Canadian Securities Administrators.
Jun 01, 2020 04:35 pm ET
Lexaria Bioscience Engages PCG Advisory, Inc, to Provide Investor Relations Services
KELOWNA, BC / ACCESSWIRE / June 1, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has retained PCG Advisory, Inc. ("PCG") of New York, to provide investor relations and digital marketing services to the Company in compliance with regulatory guidelines.
Jun 01, 2020 02:06 am ET
Lexaria Bioscience Engages PCG Advisory, Inc, to Provide Investor Relations Services
KELOWNA, BC - TheNewswire - June 1, 2020 - Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has retained PCG Advisory, Inc. (“PCG”) of New York, to provide investor relations and digital marketing services to the Company in compliance with regulatory guidelines. 
May 11, 2020 06:40 pm ET
Lexaria Bioscience Confirms Closing of US$2,039,228 Private Placement
KELOWNA, BC / ACCESSWIRE / May 11, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today confirms that its private placement financing as previously announced on May 4, 2020 (the "Offering") closed pursuant to two tranches.
May 11, 2020 04:05 am ET
Lexaria Bioscience Confirms Closing of US$2,039,228 Private Placement
KELOWNA, BC - TheNewswire - May 11, 2020 - Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today confirms that its private placement financing as previously announced on May 4, 2020 (the “Offering”) closed pursuant to two tranches.
May 04, 2020 06:20 am ET
Lexaria Bioscience Announces Over US$2,000,000 Private Placement
KELOWNA, BC / ACCESSWIRE / May 4, 2020 / Lexaria Bioscience Corp. (OTCQB:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into definitive agreements with certain qualified investors for the sale of 8,978,260 shares ("Shares") of our common stock along with common stock purchase warrants ("Warrants") to purchase up to 8,978,260 shares of our common stock in a private placement (co
May 04, 2020 04:05 am ET
Lexaria Bioscience Announces Over US$2,000,000 Private Placement
Kelowna, BC - TheNewswire - May 4, 2020 - Lexaria Bioscience Corp. (OTC:LXRP) (CSE:  LXX) (CNSX:LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into definitive agreements with certain qualified investors for the sale of 8,978,260 shares (“Shares”) of our common stock along with common stock purchase warrants (“Warrants”) to purchase up to 8,978,260 shares of our common stock in a private placement (collectively the “Offering”) for gross proceeds of over US$2 million.  The purchase price per Share is US$0.23.  The Warrant
Apr 23, 2020 07:04 am ET
Lexaria Receives Notice of Allowance for New Patent and Awards Stock Options
Kelowna, British Columbia - TheNewswire - April 23, 2020 - Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for a new patent which provides additional patent claims that protect the use of its  DehydraTECH™ technology together with cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, or vitamins in mix and serve beverage formats. 
Apr 23, 2020 06:20 am ET
Lexaria Receives Notice of Allowance for New Patent and Awards Stock Options
KELOWNA, BC / ACCESSWIRE / April 23, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, has received a Notice of Allowance from the United States Patent and Trademark Office ("USPTO") for a new patent which provides additional patent claims that protect the use of its DehydraTECH™ technology together with cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, or vitamins in mix and serve beverage formats.
Apr 21, 2020 06:20 am ET
Lexaria Bioscience Files New Patent Utilizing DehydraTECH Technology for Treatment of Infectious Diseases Including COVID-19
KELOWNA, BC / ACCESSWIRE / April 21, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, has filed an important new patent application in the United States describing the use of its DehydraTECH™ technology for the delivery of antiviral drugs. The technology would potentially be used to improve treatment options for viral infectious diseases including COVID-19, MERS, SARS, influenza, herpes, hepatitis and AIDS.
Apr 21, 2020 04:04 am ET
Lexaria Bioscience Files New Patent Utilizing DehydraTECH Technology for Treatment of Infectious Diseases Including COVID-19
Kelowna, British Columbia - TheNewswire – April 21, 2020 – Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, has filed an important new patent application in the United States describing the use of its DehydraTECH™ technology for the delivery of antiviral drugs. The technology would potentially be used to improve treatment options for viral infectious diseases including COVID-19, MERS, SARS, influenza, herpes, hepatitis and AIDS. 
Mar 24, 2020 07:04 pm ET
Lexaria Bioscience Corp. to Webcast Live at Life Sciences Investor Forum March 26
Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platform today announced that Chris Bunka, Chief Executive Officer, will present live at LifeSciencesInvestorForum.com on March 26....
Mar 24, 2020 08:30 am ET
Virtual Conference for Life Sciences Companies and Investors Broadcast Live March 26, 2020
Life Sciences Investor Forum today announced the agenda for its inaugural event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...
Mar 23, 2020 06:20 am ET
Lexaria Bioscience Expands Pharmaceutical Division to Include Lipophilic Antiviral Active Molecules for COVID-19 Treatment
KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / March 23, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, has expanded the scope and activities of its 100%-owned subsidiary Lexaria Pharmaceutical Corp., to investigate how Lexaria's patented DehydraTECHTM drug delivery technology could enhance delivery and effectiveness of certain antiviral drugs in the fight against coronavirus disease COVID-19. Lexaria intends to expand collaboration with leading laboratories in North A
Mar 23, 2020 04:03 am ET
Lexaria Bioscience Expands Pharmaceutical Division to Include Lipophilic Antiviral Active Molecules for COVID-19 Treatment
Kelowna, British Columbia - TheNewswire - March 23, 2020 – Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, has expanded the scope and activities of its 100%-owned subsidiary Lexaria Pharmaceutical Corp., to investigate how Lexaria’s patented DehydraTECHTM drug delivery technology could enhance delivery and effectiveness of certain antiviral drugs in the fight against coronavirus disease COVID-19.  Lexaria intends to expand collaboration with leading laboratories in North America and internationally as soo
Mar 19, 2020 06:20 am ET
Lexaria Bioscience Begins Coronavirus COVID-19 Drug Delivery Program
KELOWNA, BC / ACCESSWIRE / March 19, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, announces it is commencing a program, in collaboration with leading laboratories in Canada and the USA, to study the benefits of Lexaria's DehydraTECHTM drug delivery platform for enhancing delivery and effectiveness of certain antiretroviral drugs in the fight against coronavirus disease COVID-19.
Mar 19, 2020 04:03 am ET
Lexaria Bioscience Begins Coronavirus COVID-19 Drug Delivery Program
Kelowna, British Columbia – TheNewswire – March 19, 2020 – Lexaria Bioscience Corp. (OTC:LXRP) (CSE: LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery technology, announces it is commencing a program, in collaboration with leading laboratories in Canada and the USA, to study the benefits of Lexaria’s DehydraTECHTM drug delivery platform for enhancing delivery and effectiveness of certain antiretroviral drugs in the fight against coronavirus disease COVID-19.
Mar 16, 2020 02:03 am ET
Lexaria Bioscience Announces Warrant Issuance
Kelowna, British Columbia – TheNewswire – March 16, 2020 – Lexaria Bioscience Corp. (OTC:LXRP) (CSE: LXX) (CNSX:LXX.CN) (the “Company”), a global innovator in drug delivery platforms, announces that on March 16, 2020 it issued share purchase warrants (“Warrants”) to one of its Canadian-based consultants, entitling the consultant to purchase up to 500,000 common shares (“Shares”) of the Company.  The Warrants are exercisable at a price of US$0.30 per share for a period of five years expiring on March 16, 2025.
Mar 04, 2020 02:20 pm ET
Lexaria Provides Update on Two Licensed Clients
KELOWNA, British Columbia / ACCESSWIRE / March 4, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has successfully processed its first DehydraTECHTM-enabled liquid nanoemulsion for cannabidiol ("CBD") beverages for one of its licensed clients. Lexaria's client expects to begin distribution of its line of CBD beverages in select US stores soon.
Mar 04, 2020 12:03 pm ET
Lexaria Provides Update on Two Licensed Clients
Kelowna, British Columbia – TheNewswire – March 4, 2020 – Lexaria Bioscience Corp. (OTC:LXRP) (CSE: LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that it has successfully processed its first DehydraTECHTM-enabled liquid nanoemulsion for  cannabidiol (“CBD”) beverages for one of its licensed clients.  Lexaria’s client expects to begin distribution of its line of CBD beverages in select US stores soon.
Feb 13, 2020 06:20 am ET
Industry Solutions from Lexaria’s DehydraTECHTM Hemp and Cannabis Powders
KELOWNA, BC / ACCESSWIRE / February 13, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that its DehydraTECHTM-enabled CBD infused powders are now available for sale across the USA to businesses wanting to produce topicals and edibles with clinically proven performance for increased consumer satisfaction and improved stability for financial savings by industry, solving key industry problems.
Feb 13, 2020 04:02 am ET
Industry Solutions from Lexaria's DehydraTECH(TM) Hemp and Cannabis Powders
Kelowna, British Columbia – TheNewswire – February 13, 2020 – Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that its DehydraTECHTM-enabled CBD infused powders are now available for sale across the USA to businesses wanting to produce topicals and edibles with clinically proven performance for increased consumer satisfaction and improved stability for financial savings by industry, solving key industry problems.
Feb 07, 2020 04:02 am ET
Lexaria Awards Options
Kelowna, British Columbia – TheNewswire – February 7, 2020 – Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that it has issued 550,000 stock options to an insider of the Company for the purchase of up to 550,000 common shares of the Company at an exercise price of US$0.47 (the “Options”).  The Options are being issued pursuant to the Company’s shareholder approved Equity Incentive Plan and are exercisable for a period of five years without any vesting provisions.
Jan 22, 2020 06:30 am ET
Lexaria Bioscience Corp. and Cannadips Cannabis Announce Expanded Relationship Into Cannabis Oral Pouch & Dip Category
KELOWNA, BC / ACCESSWIRE / January 22, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has reached a new definitive agreement to provide its patented DehydraTECHTM technology to Cannadips' cannabis products, both in its current California market, and across all of the US.
Jan 22, 2020 04:01 am ET
Lexaria Bioscience Corp. and Cannadips Cannabis Announce Expanded Relationship Into Cannabis Oral Pouch & Dip Category
Kelowna, British Columbia – TheNewswire - January 22, 2020 - Lexaria Bioscience Corp. (OTC:LXRP) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that it has reached a new definitive agreement to provide its patented DehydraTECHTM technology to Cannadips’ cannabis products, both in its current California market, and across all of the US.  
Jan 14, 2020 06:30 am ET
Lexaria Bioscience Corp. and Cannadips CBD Announce Definitive Technology Licensing agreement for CBD Oral Pouch & Dip Category
KELOWNA, BC / ACCESSWIRE / January 14, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has reached a definitive agreement to provide its patented DehydraTECHTM technology to Cannadips CBD, the Original Smokeless CBD Dip Brand.
Jan 14, 2020 04:01 am ET
Lexaria Biosciences and Cannadips CBD Announce Definitive Technology Licensing agreement for CBD Oral Pouch & Dip Category
Kelowna, British Columbia – TheNewswire - January 14, 2020 – Lexaria Bioscience Corp. (OTC:LXRP) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that it has reached a definitive agreement to provide its patented DehydraTECHTM technology to Cannadips CBD, the Original Smokeless CBD Dip Brand.  
Jan 09, 2020 01:50 pm ET
Lexaria Provides Strategic Update from CEO
KELOWNA, BC / ACCESSWIRE / January 9, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the following strategic update. (This is a shortened version of the full Strategic Update from the CEO. For the full version, please go to www.lexariabioscience.com/news/)
Jan 09, 2020 11:01 am ET
Lexaria Provides Strategic Update from CEO
Kelowna, British Columbia – TheNewswire - January 9, 2020 – Lexaria Bioscience Corp. (OTC:LXRP) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces the following strategic update.  (This is a shortened version of the full Strategic Update from the CEO. For the full version, please go to www.lexariabioscience.com/news/)
Dec 30, 2019 07:12 am ET
Lexaria Awards Options
Kelowna, British Columbia – TheNewswire - December 30, 2019 – Lexaria Bioscience Corp. (OTC:LXRP) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that on December 30, 2019 it issued stock options to an employee to purchase up to 60,000 common shares of the Company at an exercise price of US$0.43 for a period of five years, vested over a three year term.
Nov 29, 2019 04:11 am ET
Lexaria Announces 2nd Tranche Closing of Non-Brokered Private Placement
Kelowna, British Columbia - TheNewswire - November 29, 2019 - Lexaria Bioscience Corp. (OTC:LXRP) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces it has closed the second tranche of its previously announced private placement of units (the “Offering”) as at November 28, 2019.
Nov 21, 2019 06:15 am ET
Lexaria’s Technology Now Works in Less Than 10 Minutes
KELOWNA, BC / ACCESSWIRE / November 21, 2019 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has developed additional enhancements for its industry-leading DehydraTECHTM platform that delivers THC onset of action in human pilot testing in less than 10 minutes.
Nov 21, 2019 04:11 am ET
Lexaria's Technology Now Works in Less Than 10 Minutes
Kelowna, British Columbia - TheNewswire - November 21, 2019 - Lexaria Bioscience Corp. (OTC:LXRP) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces it has developed additional enhancements for its industry-leading DehydraTECHTM platform that delivers THC onset of action in human pilot testing in less than 10 minutes.
Nov 14, 2019 04:11 am ET
Lexaria Announces Closing of Non-Brokered Private Placement
Kelowna, British Columbia - TheNewswire - November 14, 2019 - Lexaria Bioscience Corp. (OTC:LXRP) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces it has closed the first tranche of its previously announced private placement of units (the “Offering”) as at November 13, 2019.
Nov 05, 2019 12:11 pm ET
Lexaria Awards Options
Kelowna, British Columbia – TheNewswire - November 5, 2019 – Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces it has issued certain stock options.
Nov 05, 2019 06:15 am ET
Lexaria Bioscience Appoints Gregg Smith as Senior Advisor
KELOWNA, BC / ACCESSWIRE / November 5, 2019 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is very pleased to announce the appointment of Gregg Smith, Founder of Evolution VC Partners (www.evolutionvcp.com), as Senior Advisor. Evolution VC is a New York-based "culture tech" venture investment firm with more than 90 portfolio companies in many disruptive and emerging consumer-tech companies, including JUUL Labs, Pax Labs, Beyond M
Nov 05, 2019 04:11 am ET
Lexaria Bioscience Appoints Gregg Smith as Senior Advisor Evolution VC Partners participates in equity financing
Kelowna, British Columbia – TheNewswire – November 5, 2019 – Lexaria Bioscience Corp. (OTC:LXRP) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is very pleased to announce the appointment of Gregg Smith, Founder of Evolution VC Partners (www.evolutionvcp.com), as Senior Advisor.  Evolution VC is a New York-based “culture tech” venture investment firm with more than 90 portfolio companies in many disruptive and emerging consumer-tech companies, including JUUL Labs, Pax Labs, Beyond Meat, Roman, Sweetgreen, Bird, New Wave Foods, Relativity Space and m
Oct 30, 2019 04:10 am ET
Lexaria Equity Financing and Corporate Strategy Update
Kelowna, British Columbia – TheNewswire – October 30, 2019 – Lexaria Bioscience Corp. (OTC:LXRP) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces it is arranging a non-brokered private placement for gross proceeds of approximately US$1 million (the “Financing”).
Oct 24, 2019 06:15 am ET
Lexaria Applauds FDA Decision on Reduced Risk Tobacco Format
KELOWNA, BC / ACCESSWIRE / October 24, 2019 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is very pleased to report that, for the first time ever, the Food and Drug Administration (the "FDA") has authorized the marketing of oral nicotine products through the Modified Risk Tobacco Product pathway, including product categories that could benefit from Lexaria's technology.
Oct 24, 2019 04:10 am ET
Lexaria Applauds FDA Decision on Reduced Risk Tobacco Format
Kelowna, British Columbia – TheNewswire – October 24, 2019 – Lexaria Bioscience Corp. (OTC:LXRP) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is very pleased to report that, for the first time ever, the Food and Drug Administration (the “FDA”) has authorized the marketing of oral nicotine products through the Modified Risk Tobacco Product  pathway, including product categories that could benefit from Lexaria’s technology.
Oct 08, 2019 06:15 am ET
Lexaria Bioscience Provides Update on R&D Program Progress under License Agreement with Altria
KELOWNA, BC / ACCESSWIRE / October 8, 2019 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide this update on the ongoing relationship and pursuit of innovation in oral, reduced risk nicotine consumer products using Lexaria's patented DehydraTECHTM technology, underway between Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc (NYSE:MO) ("Altria") and Lexaria's majority owned subsidiary Lexaria Nicotine LLC ("L
Oct 08, 2019 04:10 am ET
Lexaria Bioscience Provides Update on R&D Program Progress under License Agreement with Altria
Kelowna, British Columbia – TheNewswire – October 8, 2019 – Lexaria Bioscience Corp. (OTC:LXRP) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to provide this update on the ongoing relationship and pursuit of innovation in oral, reduced risk nicotine consumer products using Lexaria’s patented DehydraTECHTM technology, underway between Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc (NYSE:MO) (“Altria”) and Lexaria’s majority owned subsidiary Lexaria Nicotine LLC (“Lexaria Nicotine”).
Sep 17, 2019 06:15 am ET
Peer Reviewed Clinical Journal Publishes Lexaria Bioscience's Human CBD Study Results
KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / September 17, 2019 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that final study results of the 2018 human clinical study evaluating CBD delivery and effectiveness using its patented DehydraTECHTM powered TurboCBD™ capsules have been published in the peer reviewed medical journal, “Advances in Therapy”. Advances in Therapy focuses on clinical medicine and ph
Sep 17, 2019 04:09 am ET
Peer Reviewed Clinical Journal Publishes Lexaria Bioscience's Human CBD Study Results
Kelowna, British Columbia – TheNewswire - September 17, 2019 – Lexaria Bioscience Corp. (OTC:LXRP) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that final study results of the 2018 human clinical study evaluating CBD delivery and effectiveness using its patented DehydraTECHTM powered TurboCBD™ capsules have been published in the peer reviewed medical journal, “Advances in Therapy”. Advances in Therapy focuses on clinical medicine and pharmaceutical research and has been published continually since 1984.
Sep 06, 2019 08:30 am ET
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Featured in NetworkNewsAudio Publication Discussing Innovative Drug-Delivery Discovery
via NetworkNewsAudio – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) announces the availability of a NetworkNewsAudio publication titled, “Innovative Drug-Delivery Systems Benefit Patients and Businesses.” To hear the NetworkNewsWire...
Sep 05, 2019 08:30 am ET
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Featured in NetworkNewsWire Publication Reporting on Momentous Advances in Drug-Delivery Innovation
via NetworkWire — Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view...
Aug 27, 2019 06:15 am ET
Lexaria Bioscience Announces DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Disease Conditions
More significantly the patents granted under these two new patent families include claims for the use of DehydraTECH technology with respect to not only food and beverage use, but for the first time also for pharmaceutical applications for:
Aug 27, 2019 04:08 am ET
Lexaria Bioscience Announces DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Disease Conditions
Kelowna, British Columbia – TheNewswire – August 27, 2019 – Lexaria Bioscience Corp. (OTCQX:LXRP) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that it has received a new patent granted in Australia: #2016367037 / Grant Date August 15, 2019 – “Stable ready-to-drink beverage compositions comprising lipophilic active agents”.
Aug 22, 2019 06:15 am ET
Lexaria Announces Commercial Launch of ChrgD+ Odorless, Flavorless, Water-Soluble Powdered Hemp Oil
About Lexaria
Aug 21, 2019 04:08 am ET
Lexaria Announces Commercial Launch of ChrgD+ Odorless, Flavorless, Water-Soluble Powdered Hemp Oil
Kelowna, British Columbia – TheNewswire - August 22, 2019 – Lexaria Bioscience Corp. (OTC:LXRP) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the online commercial launch of ChrgD+, the industry’s most advanced water-soluble multi-spectrum hemp oil in a powdered format and empowered with DehydraTECHTM for fast, effective delivery. For sale now to US consumers at chrgd.life
Aug 15, 2019 08:00 am ET
More Companies Lining Up to Get Their Hands on Lexarias DehydraTECH Platform -- CFN Media
Seattle, Washington--(Newsfile Corp. - August 15, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an article discussing Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and its DehydraTECH™ technology.
Aug 15, 2019 06:15 am ET
Lexaria Bioscience Announces it has Received Four New Patents
About Lexaria
Aug 15, 2019 04:08 am ET
Lexaria Bioscience Announces it has Received Four New Patents
Kelowna, British Columbia – TheNewswire – August 15, 2019 – Lexaria Bioscience Corp. (OTCQX:LXRP) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that four of its pending patent applications, via its wholly-owned subsidiary Poviva Corp., have now been granted.  The four new patents granted are as follows:
Aug 14, 2019 06:15 am ET
Lexaria’s Appoints Former Altria Group Senior Executive and Operating Company Chief to Board of Directors
FOR FURTHER INFORMATION PLEASE CONTACT:
Aug 14, 2019 04:08 am ET
Lexaria's Appoints Former Altria Group Senior Executive and Operating Company Chief to Board of Directors
Kelowna, British Columbia – TheNewswire - August 14, 2019 – Lexaria Bioscience Corp. (OTCQX:LXRP) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Brian Quigley to its board of directors. Mr. Quigley most recently spent 16 years at Altria Group, with 7 of those years spent as President and Chief Executive Officer for U.S. Smokeless Tobacco and Nu-Mark, Altria's innovation company, during the time that the existing business relationship between Altria and Lexaria was negotiated.
Aug 13, 2019 06:15 am ET
Lexaria Bioscience Receives Cannabis R&D License from Health Canada
About Lexaria
Aug 13, 2019 04:08 am ET
Lexaria Bioscience Receives Cannabis R&D License from Health Canada
Kelowna, British Columbia – TheNewswire - August 13, 2019 – Lexaria Bioscience Corp. (OTCQX:LXRP) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that its subsidiary, Lexaria CanPharm ULC., has been issued cannabis Research and Development (“R&D”) license LIC-7NONT76UNW-2019 by Health Canada with a four-year term until August 9, 2023 unless renewed.
Aug 08, 2019 06:15 am ET
Lexaria Bioscience Completes Initial Project with Canada’s National Research Council
FOR FURTHER INFORMATION PLEASE CONTACT:
Aug 08, 2019 04:08 am ET
Lexaria Bioscience Completes Initial Project with Canada's National Research Council
- No chemical modification or degradation of Active Pharmaceutical Ingredients evidenced using DehydraTECH after acidic pH stability testing
Aug 02, 2019 06:15 am ET
Lexaria Bioscience Engages Integra Consulting Group to Provide Investor Relations Services
KELOWNA, BC / ACCESSWIRE / August 2, 2019 / Lexaria Bioscience Corp. (CNSX:LXX) (OTCQX:LXRP) (“Lexaria” or the “Company”) announces it has retained Integra Consulting Group LLC (“Integra”) to provide investor relations services to the Company in compliance with regulatory guidelines.
Aug 02, 2019 04:08 am ET
Lexaria Bioscience Engages Integra Consulting Group to Provide Investor Relations Services
Kelowna, BC  - TheNewswire - August 2, 2019 - Lexaria Bioscience Corp. (CNSX:LXX.CN) (OTCQB:LXRP) (“Lexaria” or the “Company”) announces it has retained Integra Consulting Group LLC (“Integra”) to provide investor relations services to the Company in compliance with regulatory guidelines.
Jul 30, 2019 06:15 am ET
Lexaria Bioscience Summarizes its Eleven Technology Licenses
Altria Ventures Inc.
Jul 30, 2019 04:07 am ET
Lexaria Bioscience Summarizes its Eleven Technology Licenses
Kelowna, British Columbia – TheNewswire - July 30, 2019 - Lexaria Bioscience Corp. (OTCQX:LXRP) (CNSX:LXX.CN), (the “Company” or “Lexaria”) an innovator in drug delivery platforms, reports on its existing technology licensees that have signed definitive contracts to use Lexaria’s revolutionary DehydraTECHTM absorption technology within their existing and emerging brands.
Jul 24, 2019 06:10 am ET
Lexaria Bioscience and Hill Street Beverage Co. Enter Global Manufacturing & Licensing Partnership
FOR FURTHER INFORMATION PLEASE CONTACT:
Jul 24, 2019 04:07 am ET
Lexaria Bioscience and Hill Street Beverage Co. Enter Global Manufacturing & Licensing Partnership
Hill Street Licensed to Offer DehydraTECH Products, Ingredients, and Infused Beverages Worldwide.
Jul 15, 2019 08:35 am ET
Life Science Company Live Investor Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations
Jul 15, 2019 08:35 am ET
Life Science Company Live Investor Presentations Now Available for On-Demand Viewing
NEW YORK, July 15, 2019 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the July 11th life sciences conference are now available for on-demand viewing at VirtualInvestorConferences.com.
Jul 11, 2019 06:15 am ET
Lexaria Bioscience Enters CBD License Agreement with Universal Hemp
FOR FURTHER INFORMATION PLEASE CONTACT:
Jul 11, 2019 04:07 am ET
Lexaria Bioscience Enters CBD License Agreement with Universal Hemp
Kelowna, British Columbia – TheNewswire - July 11, 2019 – Lexaria Bioscience Corp. (OTCQX:LXRP) (CNSX:LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces  that it has entered a definitive 5-year agreement, via its subsidiary Lexaria Hemp Corp., to provide Lexaria’s patented DehydraTECHTM technology to Universal Hemp LLC, a B2B manufacturing company of high-performing hemp-derived bulk ingredients to the nutraceutical and consumer packaged goods industries, for utilization into many CBD-based food ingredients to be produced and sold across the USA immediately, and
Jul 10, 2019 06:10 am ET
Lexaria Bioscience Enters CBD Beverage License Agreement with Nic’s Beverages
FOR FURTHER INFORMATION PLEASE CONTACT:
Jul 10, 2019 04:07 am ET
Lexaria Bioscience Enters CBD Beverage License Agreement with Nic's Beverages
Kelowna, British Columbia – TheNewswire - July 10, 2019 - Lexaria Bioscience Corp. (OTCQX:LXRP) (CNSX:LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces  that it has entered a definitive 5-year agreement, via its subsidiary Lexaria Hemp Corp, to provide Lexaria’s patented DehydraTECHTM technology to Nic’s Beverages Ltd for use in CBD-based beverages to be produced and sold throughout the United States.
Jul 09, 2019 03:47 pm ET
Lexaria Bioscience Corp to Webcast Live at VirtualInvestorConferences.com July 11th
KELOWNA, British Columbia, July 9, 2019 /PRNewswire/ -- Lexaria Bioscience Corp (LXRP:OTCQX  LXX:CSE), based in Kelowna, BC, focused on the improved delivery of active pharmaceutical ingredients in food, beverages and topicals, today announced that Chris Bunka, CEO will present live at VirtualInvestorConferences.com on July 11th.
Jul 09, 2019 12:03 pm ET
Life Science Company Live Investor Conference July 11th
NEW YORK, July 9, 2019 /PRNewswire/ -- Virtual Investor Conferences today announced the agenda for the upcoming Virtual lnvestor Conference, the leading proprietary investor conference series.  Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 9:15 AM ET, with the first live webcast at 9:30 AM ET, on Thursday, July 11th.
Jul 09, 2019 12:00 pm ET
Life Science Company Live Investor Conference July 11th
Life science company executives will share vision and answer audience questions at VirtualInvestorConferences.com
Jul 05, 2019 04:07 am ET
Lexaria Bioscience Engages The Richmond Club to Provide Investor Relations Services
Kelowna, British Columbia – TheNewswire - July 5, 2019 - Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces that in has retained Streetwise Investors Club Inc. dba the Richmond Club to provide media services to the Company for an initial six-month term, which is automatically renewed unless terminated.  
Jun 21, 2019 12:35 pm ET
Lexaria Announces 2019 Annual and Special Meeting Results
KELOWNA, BC / ACCESSWIRE / June 21, 2019 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces the results of the 2019 Annual and Special Meeting (the "Meeting").
Jun 21, 2019 11:06 am ET
Lexaria Announces 2019 Annual and Special Meeting Results
Kelowna, British Columbia / TheNewswire / June 21, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) announces the results of the 2019 Annual and Special Meeting (the “Meeting”).  
Jun 13, 2019 08:30 am ET
Lexaria Bioscience Corp. Featured in CannabisNewsAudio Broadcast on Dramatic Results of CBD Delivery System Study
via CannabisNewsAudio – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces the availability of an audio press release titled, “Dramatically Improved Delivery Systems Promise More Effective Cannabis Treatments.” To hear the...
Jun 13, 2019 08:00 am ET
DehydraTECH: The Cynosure of Efficient CBD Delivery -- CFN Media
Seattle, Washington--(Newsfile Corp. - June 13, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP).
Jun 12, 2019 08:35 am ET
Lexaria Bioscience Corp. Featured in CannabisNewsWire Publication Describing Dramatic CBD Delivery System Improvements
via CannabisNewsWire – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces its placement in an editorial published by CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for private and public entities in...
Jun 04, 2019 06:10 am ET
Lexaria Bioscience Announces new DehydraTECH Innovation, Files New Patents
New Enhanced DehydraTECH™ Formulation Delivers 8X More CBD into Blood and Over 19X More CBD into Brain Tissue than Standard Industry Formulations.
Jun 04, 2019 04:06 am ET
Lexaria Bioscience Announces new DehydraTECH Innovation, Files New Patents
New Enhanced DehydraTECHTM formulation delivers 8X more CBD into blood and over 19X more CBD into brain tissue than standard industry formulations.
May 31, 2019 08:30 am ET
Lexaria Bioscience Corp. Featured in CannabisNewsAudio Broadcast Touting Impact of Technology on CBD Edible Space
via CannabisNewsAudio – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces the availability of a CannabisNewsAudio Broadcast titled, “Disruptive CBD Delivery Technology Could Revolutionize World of Cannabis Consumer Products,...
May 30, 2019 08:35 am ET
Lexaria Bioscience Corp. Featured in CannabisNewsWire Publication Discussing Disruptive Potential of CBD Delivery Technology
via CannabisNewsWire – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces its placement in an editorial published by CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for private and public entities in...
May 28, 2019 06:15 am ET
Combining Lexaria’s DehydraTECHTM with Nanotech Delivers Increased Quantities of CBD into Brain Tissue
Lexaria's Patented DehydraTECH Combined with Nanoemulsion Formulation Delivers 1,137% More CBD
May 28, 2019 04:05 am ET
Combining Lexaria's DehydraTECH(TM) with Nanotech Delivers Increased Quantities of CBD into Brain Tissue
Kelowna, British Columbia / TheNewswire / May 28, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces recent animal testing proves that combining Lexaria’s DehydraTECHTM delivery technology with generic nanotech techniques delivers 1,137% more cannabidiol (“CBD”)  into animal brain tissue following oral ingestion than certain existing industry formulations.
May 23, 2019 11:05 am ET
Lexaria Bioscience Announces the Issuance of Options and Warrants
Kelowna, British Columbia / TheNewswire / May 23, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces that on May 22, 2019 it issued the following securities:
May 21, 2019 06:05 am ET
Lexaria Bioscience and Nuka Enterprises' 1906 Expand Cannabis Product Relationship
1906 Fast-Acting Edibles Products, Powered by Lexaria's DehydraTECH Technology, Will Expand Across the US in 2019and 2020
May 21, 2019 04:05 am ET
Lexaria Bioscience and Nuka Enterprises' 1906 Expand Cannabis Product Relationship
1906 fast-acting edibles products, powered by Lexaria’s DehydraTECH technology, will expand across the US in 2019 and 2020
May 15, 2019 06:05 am ET
Lexaria’s DehydraTECH Formulation Delivers 475% More CBD to Bloodstream after 15 Minutes than Conventional Industry Formulations
KELOWNA, BC / ACCESSWIRE / May 15, 2019 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, has proven in animal testing that Lexaria's DehydraTECHTM technology delivers cannabinoids to the bloodstream much more quickly and effectively than conventional industry cannabinoid edible formulation designs that often combine cannabinoids with MCT oils such as coconut oil.
May 15, 2019 04:05 am ET
Lexaria's DehydraTECHTM Formulation Delivers 475% More CBD to Bloodstream after 15 Minutes than Conventional Industry Formulations
- The DehydraTECH formulation delivered measurable quantities of cannabidiol (“CBD”) into blood in as little as 2 minutes;
May 07, 2019 06:10 am ET
Lexaria Bioscience Announces CBD-Beverage Formulation License Agreement with Nevada-Based Company
KELOWNA, BC / ACCESSWIRE / May 7, 2019 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, announces that it has entered a definitive 5-year agreement, via its subsidiary Lexaria Hemp Corp, to provide Lexaria's patented DehydraTECHTM technology to a private Nevada-based company for its utilization in certain CBD-based beverages to be produced and sold across the USA.
May 07, 2019 04:05 am ET
Lexaria Bioscience Announces CBD-Beverage Formulation License Agreement with Nevada-Based Company
Kelowna, British Columbia / TheNewswire / May 7, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces  that it has entered a definitive 5-year agreement, via its subsidiary Lexaria Hemp Corp, to provide Lexaria’s patented DehydraTECHTM technology to a private Nevada-based company for its utilization in certain CBD-based beverages to be produced and sold across the USA.
Apr 25, 2019 06:05 am ET
Lexaria Bioscience Expands Advisory Board
KELOWNA, BC / ACCESSWIRE / April 25, 2019 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to announce new appointments to its Scientific Advisory Board, each of whom will contribute advice and recommendations and support related to the Company's scientific research and product development. Lexaria is honored to have the opportunity of working with each of them.
Apr 25, 2019 04:04 am ET
Lexaria Bioscience Expands Advisory Board
Kelowna, British Columbia / TheNewswire / April 25, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, is pleased to announce new appointments to its Scientific Advisory Board, each of whom will contribute advice and recommendations and support related to the Company’s scientific research and product development. Lexaria is honored to have the opportunity of working with each of them.